Clinical Trial Update: Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With Advanced Cervical Cancer. [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating VB10.16 alone or with atezolizumab for advanced cervical cancer has been withdrawn. No results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer

Drugs mentioned

• Atezolizumab (atezolizumab)
• VB10.16

Snippet

Sponsor: Nykode Therapeutics ASA | Conditions: HPV-Related Cervical Carcinoma, HPV-Related Malignancy | Phase 2 | Status: WITHDRAWN